Cargando…
Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England
BACKGROUND: England's National Institute for Health and Care Excellence (NICE) and the US’ Institute for Clinical and Economic Review (ICER) both conduct cost-effectiveness evaluations for new cancer drugs to help payers make drug coverage decisions. However, NICE and ICER assessments have been...
Autores principales: | Cherla, Avi, Renwick, Matthew, Jha, Ashish, Mossialos, Elias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788430/ https://www.ncbi.nlm.nih.gov/pubmed/33437948 http://dx.doi.org/10.1016/j.eclinm.2020.100625 |
Ejemplares similares
-
Cost‐Effectiveness of Cardiovascular, Obesity, and Diabetes Mellitus Drugs: Comparative Analysis of the United States and England
por: Cherla, Avi, et al.
Publicado: (2020) -
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021) -
Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022) -
A Framework for Digital Health Policy: Insights from Virtual Primary Care Systems Across Five Nations
por: Srivastava, Divya, et al.
Publicado: (2023) -
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps
por: Simpkin, Victoria L, et al.
Publicado: (2017)